In recent years, a large family of phosphoinositide 3-kinase (PI3K) isozymes has been characterized and cloned. Several of these PI3K enzymes have overlapping tissue distributions and it remains unclear if and how their 3-phosphoinositide products elicit differential, intracellular effects. One possibility is that the PI3K enzymes display a restricted distribution within the cell to produce their 3-phospholipid products in specific, subcellular compartments. In the present study we characterize the subcellular distribution of the novel class II PI3K isozyme PI3K-C2␣ in several mammalian cell types. Differential centrifugation of COS-1 and U937 cells together with Western blot analysis demonstrated that PI3K-C2␣ is constitutively associated with phospholipid membranes. Centrifugation of rat brain homogenates and Western blotting revealed that in contrast to the class IA PI3K enzymes, PI3K-C2␣ could be copurified with a population of clathrin-coated vesicles (CCVs). Furthermore, a PI3K activity refractory to wortmannin treatment was detected in CCV preparations consistent with the presence of the PI3K-C2␣ isozyme. These biochemical observations were supported by immunofluorescence analysis that revealed PI3K-C2␣ to have a punctate distribution and an enrichment of immunoreactivity within a perinuclear site consistent with its presence in the endoplasmic reticulum or Golgi apparatus. Dual label immunofluorescence demonstrated that in this region, the distribution of PI3K-C2␣ closely paralleled that of ␥-adaptin, a component of the AP-1 adaptor that is present in the trans-Golgi and the trans-Golgi network (TGN) resident protein TGN-46. Neither the phospholipid association nor the subcellular localization of PI3K-C2␣ was dependent upon either its COOH-terminal PX or C2 domains. Mutants lacking these domains demonstrated a similar distribution to the wild type enzyme when expressed as recombinant proteins. Treatment of cells with brefeldin A disrupted the perinuclear staining pattern of both PI3K-C2␣ and the AP-1 complex demonstrating that the localization of both molecules at the TGN is dependent upon ADP-ribosylation factor GTPase activity.
Phosphoinositide 3-kinase (PI3K) 1 was originally isolated from bovine brain as a heterodimeric complex consisting of an 85-kDa regulatory subunit and a 110-kDa catalytic subunit. Since then, additional purification strategies and reverse transcriptase-polymerase chain reaction-based approaches have identified seven other mammalian PI3K catalytic subunits. On the basis of structure and in vitro activity, these PI3K isozymes have been divided into three classes termed I, II, and III (1) . Class I further subdivides into class IA and class IB. Class IA contains p110␣, p110␤, and p110␦. Each of these PI3K subunits bind a p85-like adaptor that facilitates their translocation to phosphotyrosine-containing signaling complexes. Class IB contains the G-protein-activated enzyme p110␥. This PI3K isozyme does not bind a p85 adaptor but instead a molecule termed p101 whose function is currently unclear. In vitro, these PI3K enzymes are all able to utilize phosphatidylinositol (PtdIns), PtdIns(4)P, and PtdIns(4,5)P 2 as substrate. However, it has been suggested that PtdIns(3,4,5)P 3 is their principle product in situ (2, 3) . Class II PI3K enzymes include PI3K-C2␣, PI3K-C2␤, and PI3K-C2␥. They are distinguished from other PI3K isozymes by the presence of two tandem domains at their carboxyl terminus. The first is termed a phox homology (PX) domain and despite its presence in many eukaryotic signaling molecules, the function of this domain remains unclear (4) . The second is the C2 domain which is a phospholipid-binding module that can confer a Ca 2ϩ sensitivity (5) . The function of either domain in the PI3K enzymes is unknown. In vitro, all class II PI3K isozymes phosphorylate PtdIns and PtdIns(4)P but their spectrum of 3-phosphoinositide production in vivo remains to be determined. However, PI3K-C2␣ plays a signaling role downstream of both the receptor for the chemokine monocyte chemotactic peptide (MCP-1) (6) and the insulin receptor (7) . Both PI3K-C2␣ and PI3K-C2␤ are downstream signaling targets of activated epidermal growth factor and platelet-derived growth factor receptors. 2 In platelets, PI3K-C2␤ is activated in response to stimulation of integrin receptors by fibronectin (9) . Interestingly, although both PI3K-C2␣ and PI3K-C2␤ share a wide tissue distribution, expression of PI3K-C2␥ is restricted primarily to hepatocytes (10, 11) . Class III PI3K contains only a single enzyme termed Vps34p. In yeast, this PI3K isozyme regulates vacuolar trafficking through its generation of PtdIns(3)P. Although a mammalian homologue of Vps34p has also been characterized, most of what we understand about its function has been extrapolated from work in yeast (12, 13) .
The 3-phosphoinositides produced by PI3K activity play a pivotal role as second messenger molecules in a diverse array of physiological events. These include cell proliferation, the prevention of apoptosis, vesicle trafficking, migration and motility, receptor internalization, and glucose transport (3) . In quiescent cultures, only phosphatidylinositol 3-phosphate (PtdIns(3)P) is readily detected. However, following ligand stimulation, the intracellular concentration of PtdIns(3,4,5)P 3 transiently increases within seconds followed by a more sustained accumulation of PtdIns(3,4)P 2 (2) . Given that 3-phosphoinositides direct an array of molecules to different positions within the cell in response to different stimuli, some degree of spatial and temporal regulation of 3-phosphoinositide production must exist. Several PI3K isozymes may be found within any single cell type and although not all PI3K enzymes can produce each 3-phosphoinositide product there is often overlap in the distribution of PI3K isozymes within the same class. Although much effort has been applied to identifying distinct mechanisms of activation, little has been done to examine the subcellular localization of the PI3K isozymes.
In eukaryotic cells, the formation and transport of vesicles from both the plasma membrane and trans-Golgi network (TGN) to endosomes involves the assembly of clathrin-coated vesicles (CCVs) (14, 15) . While CCVs derived from the plasma membrane and TGN both contain clathrin as a major component, the two types of vesicles can be distinguished by their assembly or adaptor protein (AP). Thus, AP-1 is present on vesicles derived from the Golgi apparatus while AP-2 is found on vesicles produced from the plasma membrane. Both AP-1 and AP-2 are heterotetrameric complexes. AP-1 is composed of ␥ and ␤Ј adaptin (approximately 100 kDa), a 47-and 19-kDa protein. In contrast, AP-2 contains ␣ and ␤ adaptin (approximately 100 kDa), a 50-and 17-kDa protein (16, 17) . Polymerization of clathrin with AP complexes in the cell is associated with phosphoinositide interactions and an array of receptors and regulatory molecules such as the GTPase ADP-ribosylation factor-1 (18) . Tyrosine-and dileucine-based motifs represent two sorting signals contained within the cytoplasmic portion of several receptors and transmembrane glycoproteins. Such motifs mediate interactions with either the 2 subunit of AP-2 or the ␤1 subunit of AP-1 to select proteins for inclusion into the vesicle and facilitate their transfer from one part of the cell to another (19, 20) . A long outstanding question remains as to how the adaptor complexes can specifically target selected intracellular membranes.
Numerous studies suggest that one or more 3-phosphoinositides may provide at least part of the required specificity. However, it remains unclear which PI3K isozymes are involved in the control of vesicle trafficking. In this study we investigate the subcellular localization of PI3K-C2␣ with the goal of determining whether this PI3K could play a role in regulating adaptor protein function.
EXPERIMENTAL PROCEDURES
Cell Culture-Stock cultures of HEK293 and COS-1 cells were subcultured in 90-mm Nunc dishes using Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 100 units/ml penicillin and 100 g/ml streptomycin. Cultures were incubated in a humidified atmosphere of 10% CO 2 , 90% air at 37°C for 3 days. After this time, cells were switched to Dulbecco's modified Eagle's medium containing 0.5% fetal bovine serum. The cultures were confluent and quiescent 24 -48 h later. Cultures of U937 cells were passaged every 3-4 days in RPMI containing 5% fetal bovine serum and penicillin/streptomycin. Subcellular Fractionation-Cells were disrupted by 20 strokes of a small Dounce homogenizer on ice and 10 passages through a 25-gauge needle in 1 ml of Tris/sucrose buffer (0.25 M sucrose, 20 mM Tris-HCl, pH 7.4, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, 200 KIU/ml aprotonin, 1 g/ml antipain, 1 g/ml pepstatin, and 400 g/ml benzamidine). Intact cells and nuclei were removed by centrifugation at 3,000 ϫ g for 10 min. The supernatant was then centrifuged at 18,000 ϫ g for 20 min to yield a PM/TGN-enriched fraction and then at 350,000 ϫ g for 30 min. The resultant pellet was referred to as the LDM fraction and the supernatant as cytosol (21) . All centrifugations were performed at 4°C. Crude enrichment of PM/TGN and LDM from cytosol was verified by Western blotting for M6PR, TGN-46 the human homologue of the trans-Golgi resident protein TGN-38 and measurements of lactate dehydrogenase activity.
Immunoprecipitation-Quiescent cultures were washed twice with PBS and lysed at 4°C with either Triton X-100 lysis buffer (10 mM Tris-HCl, 5 mM EDTA, 150 mM NaCl, 30 mM sodium pyrophosphate, 50 mM sodium fluoride, 100 M Na 3 VO 4 , 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, 1 g/ml pepstatin, 200 KIU/ml aprotonin, and 1 g/ml antipain, pH 7.6) or Nonidet P-40 lysis buffer (20 mM Tris-HCl, 2 mM EDTA, 137 mM NaCl, 1 mM Na 3 VO 4 , 1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, and 10 g/ml each of leupeptin, chymostatin, and antipain, 15% glycerol, pH 7.5). Cell lysates were clarified by centrifugation at 15,000 ϫ g for 10 min and pre-cleared for 1 h at 4°C. The supernatants were then transferred to fresh tubes and proteins were immunoprecipitated upon addition of antibodies and protein G-agarose. Immunoprecipitates were either washed three times with lysis buffer and extracted with sample buffer (200 mM Tris-HCl, 6% SDS, 2 mM EDTA, 4% 2-mercaptoethanol, 10% glycerol, pH 6.8) or washed twice with lysis buffer and three times with kinase buffer for use in phosphoinositide kinase assays.
Western Blotting-Following extraction, proteins were fractionated by SDS-PAGE. After transfer to polyvinylidene difluoride membranes these were blocked with 5% non-fat dried milk in PBS, pH 7.4. Anti-PI3K-C2␣ antisera (1:1000), anti-p85␣ (1:500), or anti-Glu (1:700) antibody was added in PBS that contained 3% milk, 0.05% Tween 20 for 2-4 h. Following a 1-2 h incubation with horseradish peroxidaselabeled second antibody (1:5000), immunoreactive proteins were visualized using enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech).
Phosphoinositide Kinase Assay-Preparations of purified CCVs, immunoprecipitated Glu-tagged PI3K-C2␣ or p110␣ were incubated with [␥-32 P]ATP and PtdIns at 30°C for either 10 min (CCV preparations) or 30 min (PI3K-C2␣ and p110␣). The formation of radiolabeled 3-and 4-phosphoinositides was determined upon separation by thin layer chromatography and autoradiography as described previously (22) .
Preparation of PI3K-C2␣ Deletion Mutants-The PX-C2 domain and C2 domain deletion mutants were prepared by a polymerase chain reaction based strategy. The sense oligonucleotide, ccttcagggttaccagaacttac, annealed across the BstEII restriction site at nucleotide 4022. The antisense oligonucleotide, ccggaattcttagatgggctcatcattagaagg, terminated the PI3K-C2␣ cDNA at nucleotide 4224 and incorporated a 3Ј EcoRI restriction site. The antisense oligonucleotide, ccggaattcttaagacctagctatcccttcagc, terminated the PI3K-C2␣ cDNA at nucleotide 4638. Sense and antisense primers were used in a polymerase chain reaction using 5Ј Glu-tagged PI3K-C2␣-pBluescript SK plasmid as template. The 222-and 636-base pair products were purified and digested with BstEII and EcoRI enzymes together with 5Ј Glu-tagged PI3K-C2␣-pBluescript SK plasmid. Once re-purified, the inserts were ligated using T4 ligase. After sequencing, cDNA representing 5Ј Glu-tagged PI3K-C2␣, the ⌬PX-C2 and ⌬C2 domain deletion mutants were subcloned into pShooter (pEF/cyto, Invitrogen) using NcoI/XhoI. These constructs were used for expression of recombinant protein in mammalian cells.
Mammalian Cell Transfections-Cultures of HEK 293 cells (60% confluent) were transfected with 5Ј Glu-tagged PI3K-C2␣-pShooter, PX-C2 deleted (⌬PX-C2), and C2 domain deleted (⌬C2) 5Ј Glu-tagged PI3K-C2␣-pShooter plasmid (5 g/dish) using LipofectAMINE (Life Technologies) in accordance with the supplied protocol. Cells were used for experimental purposes, 48 h following transfection.
Immunostaining of Cells-Cells (1 ϫ 10 5 ) were plated onto 13-mm glass coverslips and cultured overnight with 10% fetal bovine serum in Dulbecco's modified Eagle's medium at 37°C in a humidified atmosphere containing 10% CO 2 , 90% air. The following day, cells were washed twice with PBS and fixed with 3.7% formaldehyde in PBS for 30 min at room temperature. After 6 washes with PBS, cells were permeabilized with 0.2% Triton X-100 in PBS and sites of nonspecific binding were blocked using PBS containing 5% non-fat dried milk, 0.05% Tween 20. All antibodies were added in PBS containing 0.5% non-fat dried milk, 0.05% Tween 20 which was also used for all washes. Cells were incubated with primary antibody for 90 min and after washing, FITC and TRITC second antibody was added at 1:400 final dilution for 60 min. After 6 washes and a final wash in H 2 O, the coverslips were inverted onto anti-fade mount and examined using fluorescence microscopy (Olympus). Images were captured using a cooled CCD camera (Phototronics) linked to a PC running Image ProPlus software (Media Cybernetics).
Antisera-Anti-PI3K-C2␣ antisera was produced as described previously to a NH 2 -terminal fragment of the PI3K-C2␣ protein (6) . This was affinity purified using recombinant protein and eluted with 0.1 M glycine into Tris, pH 8. Monoclonal anti-␥ adaptin AP-1 (clone 100/3) and anti-␣ adaptin AP-2 (clone 100/2) were purchased from Sigma. Monoclonal anti-Lamp-1 was a generous gift from Prof. C. Hopkins, Medical Research Council Laboratory for Molecular Cell Biology, University College, London. Rabbit anti-TGN-46 was a gift from Dr. G. Banting, University of Bristol, sheep anti-TGN-46 was a gift from Dr. S. Ponnambalam, University of Dundee. Anti-M6PR antisera were a gift from Professor P. Luzio, University of Cambridge.
Enrichment of Clathrin-coated Vesicles-Bovine brain CCVs were prepared using discontinuous sucrose density gradient centrifugation steps as described previously (16) . These partially purified preparations were further fractionated on a sucrose-D 2 O step gradient (23) . The molecular mass of the clathrin triskelion was approximated at 650 kDa. Quantification was performed by comparison of immunoblots with a 10-fold range of recombinant PI3K-C2␣ protein standards using methods previously described (24, 25) .
RESULTS

PI3K-C2␣ Is Constitutively Localized to Phospholipid Membranes-Confluent and quiescent cultures of COS-1 and U937
cells were scraped into hypotonic Tris/sucrose buffer and their plasma membranes disrupted on ice using sequential Dounce homogenization and passage through a narrow gauge needle. Differential centrifugation of successive supernatants generated two membrane-enriched fractions and cytosol. Western blot analysis demonstrated that endogenous PI3K-C2␣ protein present in both cell types was enriched in the plasma membrane/trans-Golgi network (PM/TGN) and low density microsomal fractions (LDM) (Fig. 1) . In comparison, little of this PI3K isoform was present in the cytosolic fraction (Cyt). Western blotting of the M6PR and TGN-46 confirmed the efficiency of the enrichment protocol. Each of these marker proteins predominated in the LDM and PM/TGN membrane fractions, respectively (Fig. 2, upper and middle panel) . Separation of membranes from cytosol was demonstrated by lactate dehydrogenase assay (Fig. 2, lower panel) . Our results demonstrate that PI3K-C2␣ is constitutively associated with phospholipid membranes.
Clathrin-coated Vesicles Contain the PI3K-C2␣ EnzymeThere is good evidence to demonstrate that phosphoinositides, particularly 3-phosphoinositides, bind to AP-2 adaptors (26, 27) . To evaluate the possibility that PI3K-C2␣ might be present in CCV, these were prepared from bovine brain using established procedures. Fractions containing equivalent protein loadings were then analyzed by Western blotting (Fig. 3) . Little PI3K-C2␣ immunoreactivity was detected in the low speed pellet and essentially none in the high speed supernatant, however, differential sucrose and D 2 O gradient centrifugation of the high-speed pellet yielded fractions of progressively purified CCVs. On a per microgram basis, these were dramatically increased in PI3K-C2␣ content, quantitatively in parallel to the enrichment of clathrin. Interestingly, the class I PI3K adaptor p85␣ was also detectable in these vesicle preparations confirming an earlier report (28) , however, only an extremely small proportion of the total cellular complement of this enzyme was present in CCVs and no evidence of any enrichment was apparent. Finally, quantification of PI3K-C2␣ in these CCV preparations suggests that this PI3K isozyme represents approximately 0.3% of total CCV protein. This corresponds to approximately 1 molecule of PI3K-C2␣/CCV.
In a complementary series of experiments, the formation of both PtdIns(3)P and PtdIns(4)P was detected in purified CCV fractions upon their incubation with [␥-32 P]ATP and PtdIns (Fig. 4, middle panel) . These findings are consistent with the results presented in Fig. 3 . Pretreatment of the CCV preparations with wortmannin revealed a dose-dependent inhibition of PtdIns(3)P production. However, little inhibition of enzyme activity was achieved using 10 nM wortmannin. PI3K activity was still evident using 100 nM inhibitor and only abolished using 1 M wortmannin. This dose-effect relationship was similar to that obtained using isolated PI3K-C2␣ (Fig. 4 , upper panel) but markedly contrasts with that using recombinant class I PI3K catalytic subunit p110␣ (Fig. 4, lower panel) . These observations provide functional data to support the presence of the PI3K-C2␣ enzyme to CCV preparations. 
PI3K-C2␣ Colocalizes with AP-1 Complexes at the TGN-
PI3K-C2␣ in Clathrin-coated Vesicles
tation of endogenous binding partners. This is especially relevant to both the class I and III PI3K catalytic subunits. Consequently, we used an affinity purified polyclonal antibody raised against the NH 2 terminus of PI3K-C2␣ to determine the distribution of the endogenous enzyme.
Immunostaining of Triton X-100 permeabilized HEK293 cells with anti-PI3K-C2␣ antisera revealed a punctate distribution of immunoreactivity across the entire cell with a distinctive and characteristic enrichment in a perinuclear region (Fig. 5, panels A, C, and E) . Dual labeling was performed with monoclonal anti-␣ adaptin, anti-␥ adaptin, and anti-Lamp-1 antibodies in an effort to clarify the nature of these subcellular compartments. Anti-␣-adaptin also produced a punctate staining pattern (Fig. 5, panel B ) similar to that observed for PI3K-C2␣, however, there was little evidence of overlap in these cells. In contast, immunostaining for ␥-adaptin produced a far more localized, perinuclear staining pattern (29) (Fig. 5, panel D) . Some AP-1 adaptor containing CCVs were also scattered around the cytoplasm and close to the plasma membrane. However, it was clear that at the perinuclear region, there was marked overlap between the staining patterns of ␥-adaptin and PI3K-C2␣. Although there was evidence of co-localization, this overlap was not absolute.
Lamp-1 is a heavily glycosylated protein present in lysosomal membranes (30) . Our immunostaining also revealed a localized perinuclear distribution of Lamp-1 (Fig. 5, panel F) but despite a limited degree of overlap, its pattern was quite distinct from that of PI3K-C2␣ (Fig. 5, panel E) . Even at the TGN, lysosomal membrane proteins such as Lamp-1 and Lamp-2 are packaged into vesicles that are distinct from those that carry AP-1, M6PR, and vacuolar hydroxylases (31) . Interestingly, the expression of epitope-tagged rat PI3K-C2␥ in primate COS cells suggested that this class II PI3K isozyme also has a perinuclear distribution, however, it was also shown to be present on the plasma membrane and nuclear membranes. Unfortunately, in that study, no attempt was made to characterize the nature of the perinuclear compartment (10) .
The overlap in PI3K-C2␣ and ␥-adaptin immunostaining was further examined in COS cells (Fig. 6, upper panels) . The merged image clearly shows that the distribution of the two proteins strikingly overlaps at a perinuclear region. The pres -FIG. 3. PI3K-C2␣ but not the class I PI3K adaptor p85 is highly enriched in clathrin-coated vesicles. Clathrin-coated vesicles were purified from bovine brain. Equivalent amounts of the indicated fractions (10 g) were separated by SDS-PAGE and immunoblotted with anti-PI3K-C2␣ (upper panel) or anti-p85␣ (lower panel) antibody. LSS, 10,000 ϫ g supernatant; HSS, 245,000 ϫ g supernatant; grad-1, crude coated vesicle fraction pooled from the first discontinuous sucrose gradient; grad-2, coated vesicle fraction pooled from the second discontinuous sucrose gradient; CCV, purified clathrin-coated vesicles collected after centrifugation of the fraction grad-2 through the 8% sucrose cushion in D 2 O.
FIG. 4. Functional PI3K-C2␣ activity in clathrin coated vesicles. Purified CCV were incubated with [␥-
32 P]ATP and exogenous PtdIns. The radiolabeled phosphoinositides produced were separated by thin layer chromatography as described previously (22) . Formation of PtdIns(3)P by CCV preparations was readily detectable under these conditions (arrow). Wortmannin pretreatment attenuated this lipid kinase activity in CCV preparations at concentrations higher than those required to inhibit the activity of p110␣ (lower panel) but similar to those needed to inhibit the activity of purified PI3K-C2␣ (upper panel). ence of PI3K-C2␣ at the TGN was confirmed by co-staining HEK-293 cells with anti-TGN-46 antisera (Fig. 6 , lower panels). TGN-46 is the human homologue of TGN-38, a well characterized transmembrane protein predominantly resident in the TGN (32) .
The Association of PI3K-C2␣ with Phospholipid Membranes Is Independent of Both Its C2 and PX Domains-To examine if
either the carboxyl-terminal PX domain or C2 domain that are unique to the class II PI3K enzymes were responsible for the observed membrane localization of PI3K-C2␣, two deletion mutants were produced. The first termed ⌬PX-C2 PI3K-C2␣ (encoding amino acid residues 1-1408) lacked both domains while ⌬C2 PI3K-C2␣ (encoding amino acid residues 1-1546) lacked only the latter domain. Each deletion was confirmed by cDNA sequence analysis and following protein expression each mutant could be distinguished by their migration on SDS-PAGE (data not shown).
Recombinant 5Ј Glu-tagged PI3K-C2␣ and the deletion mutants were expressed in HEK293 cells that were used to determine their subcellular localization either by immunofluorescence analysis (Fig. 7A) or differential centrifugation and Western blotting of the homogenates (Fig. 7B) . In each experiment, recombinant PI3K-C2␣ was detected with a monoclonal anti-Glu tag antibody. Immunofluorescence staining showed that recombinant PI3K-C2␣ also had a punctate staining pattern with an enrichment of the enzyme in a perinuclear region. Interestingly, deletion of the PX and/or C2 domain had little effect upon the distribution of this PI3K isozyme. Western blotting of crude membrane fractions revealed that like the endogenous enzyme, recombinant PI3K-C2␣ and each COOHterminal deletion mutant were also present in the PM/TGN and LDM fractions (Fig. 7B) . These results further suggest that the association of PI3K-C2␣ with phospholipid membranes is independent of any adaptor or binding proteins. If it were, a rapid saturation of the available sites is likely to have occurred, resulting in an increase of cytosolic PI3K-C2␣ relative to membrane fractions.
The fungal metabolite brefeldin A causes release of ␥-adaptin from its position at the TGN (33) . This results in the redistribution of AP-1-containing CCVs but it does not affect the Golgi stack. Treatment of HEK293 cells with brefeldin A produced a dramatic reorganization of both PI3K-C2␣ (Fig. 8 , panels A and C) and ␥-adaptin immunoreactivity (Fig. 8, panels B and D) from the perinuclear region into the cytoplasm. We conclude that the localization of both PI3K-C2␣ and ␥-adaptin at the TGN is dependent upon Arf-1 GTPase activity.
DISCUSSION
One of the most striking findings we report here is that the PI3K-C2␣ enzyme is constitutively associated with phospholipid membranes in mammalian cells. We demonstrate that this PI3K isozyme is enriched upon purification of CCVs and although it is widely distributed across the cytoplasm with a punctate distribution it is clearly concentrated at the TGN.
Our observations contrast with the previously reported subcellular distribution of the class IA PI3K isozymes which, in quiescent cells, are largely present within the cytoplasm as a heterodimeric complex and translocate to the plasma membrane upon ligand stimulation (28, 34) . Numerous mechanisms have been proposed to activate the catalytic activity of class IA PI3K enzymes including phosphotyrosine-stimulated conformational change and phospholipid substrate presentation (35, 36) . Clearly, if PI3K-C2␣ is present close to its phospholipid substrate then this PI3K isozyme is either constitutively active or its enzymatic activity is tightly regulated by an as yet unknown mechanism. We consider the former hypothesis un- FIG. 7 . Localization of recombinant PI3K-C2␣, ⌬PX-C2, and ⌬C2 domain deletion mutants. HEK 293 cells were transiently transfected with a cDNA plasmid containing the mammalian expression vector pShooter and either full-length 5Ј Glu-tagged PI3K-C2␣ or deletion mutants 5Ј Glu-tagged PI3K-C2␣ 1-1408 (⌬PX-C2 domains) and 5Ј Glu-tagged PI3K-C2␣ 1-1546 (⌬C2 domain). After 48 h, cultures were used for immunofluorescence staining with anti-Glu tag antibody and visualized with FITC-labeled IgG (upper panels). In addition, cells were homogenized in Tris/sucrose buffer and centrifuged to yield two membrane-enriched fractions containing plasma membrane/transGolgi network (PM/TGN), low density microsomes (LDM), and cytosol (Cyt). After SDS-PAGE, protein was Western blotted with anti-Glu tag antibody and visualized by ECL .   FIG. 6 . PI3K-C2␣ is present at the TGN. COS and HEK293 cells were stained with affinity purified polyclonal anti-PI3K-C2␣ antiserum and either monoclonal anti-␥-adaptin antibody or goat anti-TGN-46 polyclonal antisera respectively. Anti-PI3K-C2␣ antisera was visualized with TRITC-labeled anti-rabbit IgG. Anti-␥-adaptin was detected with FITC-labeled anti-mouse IgG while anti-TGN-46 was visualized using FITC-labeled donkey anti-goat IgG. Positions of protein co-localization are revealed by the isignal.
likely since transient transfection of either recombinant PI3K-C2␣ or PI3K-C2␤ into COS cells did not alter the pattern of 3-phosphorylated lipid production in these cells (data not shown and Ref. 37) . In contrast to both the class I and the class III enzymes, no binding partner has been identified for the class II PI3Ks. Given the comparatively high molecular mass of these enzymes it is possible that these PI3K enzymes contain an autoregulatory domain to modulate their catalytic activity. Arcaro et al. (37) has suggested that the C2 domain of PI3K-C2␤ may act as a negative regulator of its catalytic activity by sequestering lipid substrate, however, further work is required before this hypothesis can be extrapolated to other class II PI3K enzymes.
Our biochemical localization of PI3K-C2␣ to phospholipid membranes and CCVs (Figs. 1-4 ) was confirmed by immunofluorescence. Although PI3K-C2␣ immunoreactivity was distributed across the cytoplasm in a punctate manner it was strikingly localized at the TGN in close proximity to ␥-adaptin (Figs. 5 and 6) (17, 29) . Interestingly, although there was considerable overlap between the staining patterns of these two proteins, they did not fully co-localize. However, brefeldin A treatment did disrupt the distribution of both proteins (Fig.  8) suggesting that they share a common mechanism of localization. Brefeldin A is a fungal metabolite originally found to produce extended tubular structures from the Golgi apparatus and redistribute Golgi components to the endoplasmic reticulum. In addition, it induces the formation of membranous tubules at both the TGN and endosomes (38, 39) . These effects are produced by its inhibition of ADP-ribosylation factor and AP-1 binding to the TGN and ␤COP binding to the cis-Golgi (40) .
A modulatory role for 3-phosphoinositides in the control of vesicular traffic has been clearly established. At the plasma membrane these phosphoinositides are required for transport of internalized receptor to the lysosome (41, 42) whereas at the TGN, they regulate vesicle traffic to endosomes (43, 44) . In contrast, less is understood about how 3-phosphoinositides produce these effects and which PI3K enzymes are responsible for their production. Over the last 2-3 years the protein domains that mediate the action of 3-phosphoinositides have been elucidated. PtdIns(3)P binds a double zinc finger motif termed the FYVE domain present in an assortment of molecules that regulate various aspects of vesicle trafficking (45) (46) (47) . Both PtdIns(3,4)P 2 and PtdIns(3,4,5)P 3 bind pleckstrin homology domains present in a number of signaling molecules (48, 49) . In this way, 3-phosphoinositides orchestrate the translocation of molecules to signaling complexes at phospholipid membranes and in some cases directly regulate their enzyme activity. The binding of the 2 chain of purified AP-2 complexes with proteins is also enhanced by both PtdIns(3,4)P 2 and PtdIns(3,4,5)P 3 (50) . Interestingly, the interaction between dileucine-containing peptides and the ␤1 subunit of AP-1 was inhibited by the same 3-phosphoinositides (19) . In this way, the products of PI3K activity could ensure the specific interaction of transmembrane proteins with one adaptor complex but not another. In addition to binding clathrin (51) , synaptotagmin (52), Grb2, and the EGF receptor-binding protein Eps15 (53) , the ␣ chain of AP-2 has also been shown to bind inositol phosphates and 3-phosphoinositides (27) . The physiological relevance of the last observation has been demonstrated in a recent study in which the phosphoinositide binding ability of the AP-2 ␣ subunit was abrogated. AP-2 complexes containing the mutant ␣ subunit assembled properly but were not incorporated into coated pits (54) . Similarly, arrestin 3 lacking a functional phosphoinositide-binding site was incapable of effectively mediating the concentration of activated ␤ 2 -adrenergic receptor in coated pits (55) . Consequently, 3-phosphoinositides appear to regulate two of the four subunits that form the AP-2 adaptor. It will be interesting to see if additional AP-1 subunits also bind these phospholipids.
Since it is widely considered that the class IA PI3K enzymes are intimately involved in signal transduction at the plasma membrane they are unlikely to regulate protein trafficking from the TGN. Because of the seminal work on yeast Vps34, the mammalian homologue of this class III PI3K is considered to be the principle mediator of vesicle transport from the TGN to lysosomes, the organelle in mammalian cells that is functionally equivalent to the yeast vacuole. Transport of newly synthesized lysosomal enzymes from the TGN can be inhibited by the PI3K inhibitor wortmannin (43, 56) . However, these effects are observed over a wide range of concentrations (IC 50 10 -100 nM) depending upon the cell type chosen suggesting the involvement of PI3K isozymes in addition to the wortmanninsensitive human Vps34p homologue (13) . Furthermore, direct extrapolation from the yeast model to mammalian cells may be somewhat simplistic since in yeast, Vps34p is the only PI3K and PtdIns3P their principal 3-phospholipid product. Because of their greater complexity, mammalian cells may have evolved and recruited additional PI3K isoforms to produce a larger spectrum of 3-phosphoinositide products to broaden the number of target sites available for an individual phospholipid vesicle.
The class II PI3K isozymes are distinguished by the presence of two adjacent domains in their carboxyl terminus. The C2 or CalB domain that was originally identified in protein kinase C (57) appears to have diverged in evolutionary terms into Ca 2ϩ -dependent and Ca 2ϩ -independent phospholipid binding forms (5) . The C2 domain present on each of the class II PI3K enzymes binds phospholipids in a Ca 2ϩ -independent manner (37, 58) . Even less is known about the functional role of the PX domain but it has been proposed to mediate protein-protein interactions (4). PX domains are often associated with events that involve the actin cytoskeleton, GTP-binding proteins, and phospholipid membranes (59) . Somewhat surprisingly, our data demonstrates that neither the PX domain nor the C2 domain are responsible for the interaction of PI3K-C2␣ with membranes (Fig. 7) . Consequently, the mechanism responsible for their localization remains to be established. Despite the extended NH 2 terminus of the class II PI3K enzymes we have yet to identify any additional phospholipid-binding domains within this region. Similar observations were recently made with the PI3P-binding FYVE domain. Deletion of this domain from both Vac1p and Hrs did not alter the membrane localization of either protein (45, 46) . Although the membrane localization of PI3K-C2␣ could be achieved via a protein-protein interaction, immunoprecipitation of PI3K-C2␣ from cell lysates has not yet revealed any proteins which co-immunoprecipitate in a high stoichiometry.
Identification of PI3K isozymes responsible for driving vesicular traffic from the mammalian TGN has proved somewhat elusive. An apparently novel PI3K appears to act synergistically with the phospholipid transfer protein PITP and is present in a complex termed p62(cplx) (60) . This PI3K was characterized as a 100-kDa protein that associates with TGN-38 (61). However, we had previously demonstrated a Vps34p-like enzyme activity in association with human PITP (62) . Another study has isolated a 250-kDa PI3K in association with TGN-46 the human homologue of TGN-38 (32) . It remains to be established if different PI3K isozymes fulfil the same functional role in rodent and man or if indeed two distinct PI3K isozymes are involved.
As we begin to appreciate the role PI3K activity plays in vesicle trafficking, it is becoming ever clearer that the study of signal transduction and membrane trafficking can no longer remain mutually exclusive disciplines. The ability to constantly select and redistribute receptors through coated pits and the endosomal network allows cells to respond quickly to alterations in their external environment. Consequently, these events are highly dynamic and require tight regulatory control. The internalization of epidermal growth factor receptor (EGFR) into a clathrin coat by an AP-2-mediated mechanism provides a good example (63) . In addition to receptor downregulation, internalization of receptor subunits also serves to modulate receptor tyrosine kinase signaling pathways. Using an internalization defective cell line it was shown that EGFRmediated tyrosine phosphorylation and mitogen-activated protein kinase activation were both attenuated in internalization defective cells (64) . This suggests that certain steps of the signaling cascade can only be effected within specific intracellular compartments. The adaptor proteins appear to co-ordinate this specificity since in addition to EGFR⅐AP-2 complex formation at the plasma membrane, EGFR also interacts with AP-1 in large perinuclear endosomes (63) .
Many questions remain regarding the function of PI3K-C2␣ in the context of adaptor complex function. Since PI3K-C2␣ is present on CCVs and resides in the TGN close to the AP-1 adaptor, this suggests that its production of PtdIns(3)P could drive vesicle formation and traffic them from the TGN to endosomes. PI3K-C2␣ may contribute to the formation of CCVs at receptors such as the M6PR (65) or other membrane-associated protein complexes that selectively bind APs (8) . Previously, we have shown that PI3K-C2␣ is a downstream target for a growing number of receptors located in the plasma membrane. It is therefore possible that PI3K-C2␣ is involved in some aspect of receptor mediated signaling even after its internalization. In this way it may continue to disseminate the signaling cascade within the interior of the cell in a coordinated and localized manner. This proposition warrants further experimental analysis.
